Search
tropsium chloride/xanomeline (Cobenfy, KarXT)
Indications:
- treatment of schizophrenia [1] FDA-approved [2]
Dosage:
- twice daily titrated to effect
- maximum daily dose: 250 mg of xanomeline & 60 mg of trospium
Interactions
drug adverse effects of antipsychotic agents
General
pharmacologic combination
antipsychotic agent
References
- Brannan SK, Sawchak S, Miller AC et al
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist
for Schizophrenia.
N Engl J Med 2021; 384:717-726 Feb 25
PMID: 33626254
https://www.nejm.org/doi/full/10.1056/NEJMoa2017015B
- Brooks M
FDA OKs First-in-Class Antipsychotic for Schizophrenia.
Medscape. Sept 27, 2024
https://www.medscape.com/viewarticle/fda-oks-first-class-antipsychotic-schizophrenia-2024a1000hno
Components
tropsium
xanomeline